A non-randomized, open-label, single-dose study to investigate the intrapulmonary penetration of RO7223280 following intravenous administration in healthy participants
Latest Information Update: 05 Sep 2022
Price :
$35 *
At a glance
- Drugs Zosurabalpin (Primary)
- Indications Acinetobacter infections
- Focus Pharmacokinetics
- Sponsors Roche
- 04 Sep 2022 Status changed from recruiting to completed.
- 31 Mar 2022 New trial record
- 28 Mar 2022 Status changed from not yet recruiting to recruiting.